ArticleCureus2026
Quad Fever After a Traumatic Cervical Spinal Cord Injury: Diagnostic Challenges and Therapeutic Response to Bromocriptine.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Quad fever is a rare, potentially fatal form of neurogenic hyperpyrexia occurring after high cervical or upper thoracic spinal cord injury (SCI) and is frequently misdiagnosed as severe infection. It is characterised by extreme, non-infectious hyperthermia resulting from autonomic and central thermoregulatory dysfunction. We report the case of a previously healthy 72-year-old woman who sustained a traumatic C4-C5 SCI and developed abrupt postoperative hyperpyrexia (40.9 °C) within 12 hours of anterior cervical decompression and fusion. Despite antipyretics, broad-spectrum antibiotics, and physical cooling, daily high-grade fevers persisted. An extensive evaluation excluded infectious, inflammatory, endocrine, neoplastic, and hardware-related causes, with normal inflammatory markers and sterile cultures. Based on the clinical context and exclusion of alternative etiologies, a diagnosis of quad fever was established. Enteral bromocriptine 5 mg twice daily was initiated based on its dopaminergic modulation of hypothalamic thermoregulation, resulting in complete defervescence within 24 hours and sustained apyrexia thereafter, without adverse effects. This allowed the patient to continue a structured rehabilitation programme and be discharged in good general condition. This case underlines quad fever as a diagnosis of exclusion in patients with severe SCI and refractory fever, illustrates the potential morbidity and resource use associated with delayed recognition, and supports the role of bromocriptine as a promising therapeutic option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.